nonsteroidal antiandrogen developed bristolmyers squibb treatment prostate cancer never acts potent competitive antagonist androgen receptor ar ki nm halfmaximal inhibitory concentration drug found higher affinity ar bicalutamide cells showed antiandrogenic activity bicalutamide may weak partial agonist activity androgen transformed metabolite reduced cytosolic three compounds show similar antiandrogenic addition antiandrogenic activity shows activity negative allosteric modulator gabaa receptor produce seizures animals sufficiently high also shows druginduced qt reached phase clinical trials prior discontinuation clinical development terminated due occurrence seizure patient phase drug article relating genitourinary system stub help wikipedia expanding antineoplastic immunomodulatory drug article stub help wikipedia expanding